Home

Mucinous ovarian cancer recurrence

Conclusions: Recurrence occurred in both types of stage I mucinous ovarian cancer. However, lethal recurrences were observed mainly in infiltrative type Extremely poor postrecurrence oncological outcome for patients with recurrent mucinous ovarian cancer. Kajiyama H(1), Mizuno M, Shibata K, Kawai M, Nagasaka T, Kikkawa F. Author information: (1)Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsuruma-cho 65, Showa-ku, Nagoya, 466-8550, Japan, kajiyama@med. Mucinous ovarian cancer (MOC) is a rare subtype of epithelial ovarian carcinoma (EOC). Whereas all EOC subtypes are addressed in the same way, MOC is a distinct entity. Appreciating the pathological features and genomic profile of MOC may result in the improvement in management and, hence, the prognosis The time to recurrence is the amount of time between your response to a prior platinum-based chemotherapy and the time of the recurrence. If the time to recurrence is less than six months, the ovarian cancer is classified as platinum-resistant, and the woman will be treated with usually one other type of chemotherapy drug 1. Introduction. Over 200,000 patients are diagnosed annually with ovarian cancer worldwide [].Of these, mucinous ovarian cancer is a rare subtype, accounting for less than 5% of all epithelial ovarian cancers, and is associated with resistance to traditional chemotherapy and worse prognosis following recurrence [, , , , , , ].Most data on mucinous ovarian cancer are derived from trials in.

Objectives: We evaluated four different treatment regimens for advanced-stage mucinous epithelial ovarian cancer. Methods: We conducted a multicenter randomized factorial trial (UK and US). Patients were diagnosed with primary mEOC: FIGO stage II-IV or recurrence after stage I disease. Treatment arms were paclitaxel-carboplatin, oxaliplatin-capecitabine, paclitaxel-carboplatin-bevacizumab, or. Dear Leigh, Epithelial ovarian tumors are classified by cell type and by malignant potential. So tumors are grouped as benign borderline malignant (invasive) and within these 3 subtypes , the different cell types are: serous mucinous endometrioid clear cell brenner /transitional cell undifferentiated (only for invasive category) some tumors have all 3 subtypes -benign,borderline, and invasive.

Characteristics and Prognosis of Stage I Ovarian Mucinous

  1. Though ovarian cancer could come back anywhere in your body and cause a wide variety of noticeable problems, it most commonly recurs close to the original cancer in your abdomen, where typical..
  2. Ovaries are the reproductive organs where eggs are made. When cancer develops in the ovaries, it's known as ovarian cancer. Multiple treatments are available to help bring ovarian cancer into..
  3. Mucinous ovarian carcinoma have a poorer prognosis compared with other histological subtypes. The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer. The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed.
  4. Mucinous Cystadenoma- Rare Type of Ovarian Tumor There are different types of ovarian tumors affecting the human body. Of these 15- 20 % are Mucinous Cystadenoma. These tumors are characterized by cystic masses separated by septa with thin walls. They can be identified using imaging techniques such as CT scan, MRI, or ultrasound
  5. Hello, ladies, My mother is a stage 4 ovarian cancer survivor firstly diagnosed in December 2020. She's currently on Lynparza (BRCA positive, started September 2020) and she feels good. Right now I'm concerned about the very slight rise of her CA125. During her treatment, it went down from >3000 to 9

Extremely poor postrecurrence oncological outcome for

Background: According to the International Federation of Gynecology and Obstetrics (FIGO) guidelines, every patient diagnosed with ovarian cancer (OC) should undergo a complete staging procedure to adequately assess tumor spread. The role of lymphadenectomy in the initial management of primary early mucinous ovarian cancer (MOC) remains unclear , the five-year survival rate of pure mucinous carcinoma is around 96 percent. When it's mixed with other types of cancer, the five-year survival rate is 87 percent. This rate is for disease-free.. The American Cancer Society relies on information from the SEER* database, maintained by the National Cancer Institute (NCI), to provide survival statistics for different types of cancer. The SEER database tracks 5-year relative survival rates for ovarian cancer in the United States, based on how far the cancer has spread A: For decades, mucinous ovarian cancer was classified as grade 1, 2, or 3 according to the presence or absence of nuclear atypia and the proportion of solid glandular component. However, in 2014, the World Health Organization introduced a new diagnostic classification of mucinous ovarian carcinoma, with two categories according to the growth. Serum cancer antigen 125 (CA125) has been routinely used to monitor the response of patients with EOC to chemotherapy, disease progression, and recurrence. 6, 7 In MOC, however, the association between preoperative serum CA125 and survival is weak. 8 In fact, carcinoembryonic antigen (CEA) level is elevated more frequently than CA125 in.

Mucinous Cancer of the Ovary: Overview and Current Statu

Further, it has been suggested that the etiology of mucinous ovarian cancer is separate from that of other histologic subtypes[31, 32], and that mucinous ovarian tumors are associated with worse prognosis and poorer response to chemotherapy[33, 34]; it is possible mucinous tumors are similarly associated with greater risk of obstruction This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of ovarian low-malignant potential tumors. It is intended as a resource to inform and assist clinicians who care for cancer patients

Ovarian Cancer Recurrence and Treatment OCR

Preferred chemotherapy regimens for early-stage ovarian cancer include: 3-6 cycles of carboplatin plus paclitaxel (6 cycles in patients with high-grade serous, endometrioid or clear-cell ovarian cancer) 6 cycles of carboplatin. The chemotherapy regimen may be adapted if you are older and/or if you have pre-existing comorbidities such as. Borderline ovarian tumors (BOT) account for 15-20% of all ovarian tumors [].Compared to invasive epithelial ovarian cancers, BOT occurs more commonly at a younger age, during the time of optimum fertility [].BOT patients have a good prognosis with 5- and 10-year survival rates of 95 and 92.8% respectively, and recurrence rates of 5-8% [3-5] The frequency of recurrence is higher in cases of bilateral affection of ovaries (IB stage), collapse of a capsule prior to the surgery. Sonography is a highly informative method of diagnostics of BOT relapse with its sensitivity 83.5%, specifity — 64%, favorable prognostic possibility — 56%, unfavorable prognostic possibility — 66.4% Not only was serous histotype identified as a significant risk factor for recurrence due to its higher frequency of bilateral ovarian involvement, but the mucinous histotype was also related to a higher recurrency rate if treated only with cystectomy when the definition of free tumor margin is limited [64, 65]

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer, 8 (2008), p. 252. View Record in Scopus Google Scholar. H. Kajiyama, et al Response to platinum in the recurrent setting: The Study of an Ovarian Cancer cohort Recurred After first-line Treatment: a retrospective Survey showed that mucinous ovarian carcinoma have a poorer prognosis compared with other histological subtypes with platinum based chemotherapy in recurrent platinum sensitive setting, with lower response.

Abstract. Mucinous ovarian carcinomas (MOCs) are an uncommon subset of epithelial neoplasms, both clinically and molecularly distinct from other ovarian cancers. Pathologic diagnosis proves challenging, and metastatic disease from other sites—especially the digestive tract—must be excluded. Fortunately, most patients are diagnosed at an. If you have a mucinous type of borderline ovarian tumour, your doctor might also remove your appendix. This is because mucinous tumours can sometimes start in the appendix and then spread to the ovary. Most women are cured with surgery. If a borderline tumour does come back, you have more surgery However, the rates vary between the histologic subtypes. Although the rate for high-grade serous carcinoma and also low-grade serous carcinoma rises above 10%, the rate in patients with low-grade endometrioid ovarian cancer or expansile mucinous ovarian cancer is less than 2% most common type of ovarian carcinomas, accounting for approximately 10% [7]. However, the true percentage of primary mucinous ovarian tumors is actually estimated around 2.4%, since many mucinous ovarian tumors are truly sites of metastasis from gastrointestinal sources to the ovary [8]

Mucinous type of malignant tumor of the ovary is a fairly rare form of the disease, which affects 5-10% of all cancerous pathologies of this organ. The high rate of development and spread of the disease leads to the fact that the recurrence of mucinous ovarian cancer for a short period of time leads the patient to death Another rare type of epithelial ovarian cancer, clear cell carcinoma accounts for 5-10% of all ovarian cancers, and is thought to often arise from endometriosis within the peritoneal cavity.As with mucinous carcinoma, most patients present with early-stage disease, and prognosis when caught in early stages is similar to prognosis for high-grade serous, while prognosis for disease caught in. Mucinous Adenocarcinoma of Ovary is a common malignant ovarian tumor that generally affects middle-aged women. The causal factors for Mucinous Adenocarcinoma of Ovary are unknown, but genetic mutations such as mutations in KRAS gene have been reported in some cases. Tumors of the ovaries can be benign, borderline or low malignant potential (LMP. Benign Mucinous Cystadenoma of Ovary is a common benign ovarian tumor that generally affects women in their fourth decade. The causal factors for Benign Mucinous Cystadenoma of Ovary are unknown. Tumors of the ovaries can be benign, borderline or low malignant potential (LMP), or malignant tumors. Thus, not all ovarian tumors are cancers

Long term survival outcomes of stage I mucinous ovarian

mucinous ovarian cancer. hailemum •. 1 year ago • 3 Replies. After debulking December 2019, I was diagnosed with stage 1a mucinous OC, Consultant said all I would need would be physical examination in 6 months. he said I don't need blood test or scans. I am concerned that it won't be enough to know all cancer gone and no recurrence Mucinous carcinoma can be a type of cancer in any part of the body that produces mucus. The risk factor for a particular mucinous carcinoma will depend on the area of the body it affects In case of the mucinous carcinoma of the breast, lumpectomy is the best procedure to cure the disease.This procedure involves the removal of the carcinoma tissues and a layer of surrounding healthy tissue to avoid the chance of recurrence of mucinous carcinoma

Source: American Cancer Society Stage 3 Treatment. Treatment for Stage III ovarian cancer is the same as for Stage II ovarian cancer: hysterectomy and bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes), debulking of as much of the tumor as possible, and sampling of lymph nodes and other tissues in the pelvis and abdomen that are suspected of harboring cancer Update proposed the question regarding whether all patients with recurrent ovarian cancer (ROC) need systemic therapy. The response rates to systemic therapy are low in patients with recurrent/metastatic clear cell and mucinous ovarian cancers and the overall prognosis is worse than that among patients with the more common high-grade serous. Stage 1c mucinous ovarian cancer. KT57. I have just been diagnosed with stage 1c mucinous ovarian cancer. Although the tumour appeared intact there were some cancer cells found in fluid in the abdomen. I had everything removed - am 50 so long past having children. I have done quite a bit of research on this type of tumour and am a bit confused

N Engl J Med 2019; 380:1256-1266. DOI: 10.1056/NEJMra1813254. Editors. Dan L. Longo, M.D., Editor. Mucinous ovarian cancer accounts for 3% of epithelial ovarian cancers and must be distinguished. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: Results from the SOCRATES retrospective study. Article. Full-text available Right now, mucinous ovarian cancer is treated a lot like other epithelial ovarian cancers, said Kurnit, a fellow in gynecologic oncology at The University of Texas MD Anderson Cancer Center Abstract. Mucinous ovarian cancer represents approximately 3% of epithelial ovarian cancers (EOC). Despite this seemingly low prevalence, it remains a diagnostic and therapeutic conundrum that has resulted in numerous attempts to adopt novel strategies in managing this disease

Low value of staging in detecting extraovarian occult

Video: An international, phase III randomized trial in patients

Recurrence of Mucinous tumor - Ovarian Cancer - MedHel

In stage 2 ovarian cancer, the cancer is in one or both ovaries and has spread to elsewhere within the pelvis. Stage 2A means it has gone from the ovaries to the fallopian tubes, the uterus, or to. 42 year old woman with ovarian borderline mucinous tumor accompanied by low grade endometrial stromal sarcoma with myxoid change (Eur J Med Res 2017;22:52) 53 year old woman with mucinous borderline tumor with pulmonary and pleural metastasis ( Front Med (Lausanne) 2020;7:571348 C.P. Crum, C.A. Gasper, in Pathobiology of Human Disease, 2014 Mucinous Tumors. Mucinous tumors of the ovary display a spectrum of changes similar to their endometrioid and low-grade serous tumor counterparts. The major difference is the relative rarity of benign mucinous epithelium in the ovarian cortex in contrast to CICs and endometriosis

What to Know About Ovarian Cancer Recurrenc

  1. • If peritoneal implants→risk of recurrence and potentially progression to low-grade serous carcinoma responsible for most ovarian cancer deaths Often bilateral and exophytic Primary Ovarian Mucinous Borderline Tumor Secondary involvement by a Low-grade Appendiceal Mucinous Neoplasm (LAMN).
  2. Ovarian cancer is the leading cause of death in women diagnosed with gynecological cancers. It is also the fifth most frequent cause of death in women, in general.[1] Most of the cases are diagnosed at an advanced stage, which leads to poor outcomes of this disease. The existing screening tests have a low predictive value contributing further to this misery
  3. Mucinous ovarian tumors are a rare histological type of epithelial ovarian cancer (EOC), representing 2-4 % of these malignancies [1-4].Primary mucinous ovarian carcinomas are distinct from other EOC in both presentation and outcome [3, 5-8].Believed to develop along a continuum from benign cysts to borderline tumors to invasive carcinomas, the majority of cases present as borderline.
  4. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 4.2017 — November 9, 2017 Recurrent Disease (OV-5) Disease Status, Therapy for Persistent Disease or Recurrence (OV-6) versus primary mucinous ovarian cancer. LCOH-7 Added Chest/abdomen/pelvic CT with contrast for residual disease
  5. Epithelial ovarian tumors include serous, mucinous, endometrioid, clear cell, and undifferentiated tumors. In general, the likelihood of malignancy increases with increasing solid-tissue elements and thicker septa. Surgery is central to the management of ovarian cancer. Ovarian cancer recurrence: value of MR imaging
  6. Mucinous tumors are part of the surface epithelial-stromal tumor group of ovarian neoplasms, and account for approximately 36% of all ovarian tumors. Approximately 75% are benign, 10% are borderline and 15% are malignant.Rarely, the tumor is seen bilaterally; approximately 5% of primary mucinous tumors are bilateral. Benign mucinous tumors are typically multilocular (have several lobes), and.
  7. Metastatic ovarian cancer is an advanced stage malignancy that has spread from the cells in the ovaries to distant areas of the body. This type of cancer is most likely to spread to the liver, the fluid around the lungs, the spleen, the intestines, the brain, skin or lymph nodes outside of the abdomen

Ovarian Cancer Recurrence: Rates, By Stage, and Mor

Background. Mucinous tumours are defined by the presence of epithelial cells containing intracytoplasmic mucin. Mucinous ovarian tumours may resemble those of the endocervix, gastric pylorus or bowel,1 and represent the second most common type of surface epithelial-stromal tumour of the ovary, accounting for approximately 15% of all ovarian tumours.2 Similar to their serous ovarian. Data from a retrospective study suggests an adjuvant gastrointestinal (GI)-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous ovarian cancer, said Katherine C. Kurnit, MD. 1 Right now, mucinous ovarian cancer is treated a lot like other epithelial ovarian cancers, said Kurnit, lead author and a fellow in gynecologic oncology at The. It is estimated that there will be 22,530 new cases of ovarian cancer diagnosed in 2019 in the United States, and despite advances in treatment, an estimated 13,980 women will die of the disease. 1 Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study BMC Cancer , 8 ( 2008 ) , p. 25

Activity of chemotherapy in mucinous ovarian cancer with a

  1. Furthermore, as most mucinous BOT were unilateral (in contrast to serous BOT that can be bilateral in 10-20% of cases), a salpingo-oophorectomy should be performed rather than a cystectomy to avoid the risk of a (potentially lethal) recurrence in the form of invasive cancer (Nomura et al., 2004; Koskas et al., 2011)
  2. Clinical trials are research studies that involve people. The clinical trials on this list are for ovarian cancer. All trials on the list are supported by NCI. NCI's basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease
  3. BackgroundMucinous ovarian carcinoma have a poorer prognosis compared with other histological subtypes. The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer.MethodsThe SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian.
  4. e the association between prognosis and invasive patterns of ovarian mucinous carcinoma and to investigate the biomarkers of the diagnosis and prognosis immunochemically. Patients with ovarian mucinous carcinoma at our institution between.
  5. Recently, splenectomy was often included in the cytoreductive surgery of the ovarian cancer [ 2, 3, 19 ]. CT scanning and measurement of serum tumor markers, especially CA 125, are helpful for detecting the recurrence and the infrequent splenic metastasis. We proposed that splenectomy be a proper therapeutic modality for an isolated splenic.

Mucinous Cystadenoma Mucinous Medica

Mucinous Carcinomatosis: A Rare Association between an

Through the Ovarian Cancer SPORE of the DF/HCC, several of the most urgent questions in ovarian cancer therapy will be addressed. PARP inhibitors are now increasing being used to treat women with high grade serous ovarian cancer (HGSC) in both the newly diagnosed as well as recurrent settings This study aimed to investigate the clinical and pathological characteristics, and the recurrence and prognostic factors of borderline ovarian tumors (BOTs). The data of 286 patients admitted to hospital and followed up for more than ten months were analyzed retrospectively to study the clinicopathological characteristics and related factors of recurrence Both are symptoms of ovarian cancer, although less common ones. Roubinek had serous carcinoma, the most common type of ovarian cancer, which accounts for more than half of diagnoses. Less common types include clear cell, mucinous and endometrioid carcinoma. The rate of recurrence doesn't vary greatly by disease subtype but rather by the.

Mucinous Ovarian Cancer Stage 1C. Moneill1211. Hello, My name is Mike and wife (31 years old) was recently diagnosed with stage 1C (grade 2) Mucinous Ovarian Cancer. I read one story of a survivor with stage 4 ovarian cancer that had a recurrence a year after her first diagnosis and underwent more chemo and had been in remission for eight. Primary mucinous ovarian carcinoma (MOC) represents a biochemically and genetically distinct subgroup of epithelial ovarian cancer (EOC) [].MOC accounts for 3% [] to 10% [] of all ovarian carcinomas.Most patients with MOC are diagnosed at an early stage and therefore it confers a favorable prognosis [].However, once the disease is advanced, mucinous histology has a poorer outcome compared to. Epithelial ovarian cancer is a heterogeneous disease with a heterogeneous distribution pattern [2]. Epithelial ovarian cancer set by the World Health Organization recognizes eight histological tumour subtypes: serous, mucinous, endometrioid, clear cell, transitional cell, squamous cell, mixed epithelial and undifferentiated [3] An ovarian mucinous tumor can mimic appendiceal metastases. E-GIST is a mesenchymal tumor that can arise from the omentum, retroperitoneum, mesentery, or pleura. We present a case of an 87-year-old woman with mucinous carcinomatosis and acute intestinal occlusion submitted to an emergency laparotomy. She has found to have a borderline mucinous.

An extensive review of the literature on the subject of primary mucinous ovarian cancer and metastatic ovarian tumors was carried out. The data was obtained through a database search using a combination of the MeSH (Medical Subject Headings) terms mucinous, carcinoma, ovary, ovarian, immunohistochemistry, primary and metastatic Mucinous Cancer Treatment Though Mucinous Cancer do not spread as fast as the other types of cancers and are not aggressive it is easy to treat this type of cancer. It is necessary to treat this cancer and remove the cancer cells from the body. The recurrence of mucinous cancer should be prevented to improve the quality of life of the patient

Recurrence Ovarian Cancer Community - Inspir

  1. The American Cancer Society estimates that, in 2020, about 21,750 American women will be diagnosed with ovarian cancer and 13,940 women will die from the disease. Factors associated with increased risk of ovarian cancer include family history of ovarian cancer, abnormalities in BRCA genes, age (about half of all ovarian cancer patients are.
  2. al pain, vaginal bleeding, and increased abdo
  3. Objective This study aimed to evaluate the clinicopathologic features of mucinous borderline ovarian tumors (MBOTs), with an emphasis on the risk factors for recurrence. Methods Data of 76 patients with MBOT diagnosed and treated between 2000 and 2007 at a single institution were analyzed in this retrospective study. The clinicopathologic features of different tumor subgroups were analyzed.
  4. Purpose To evaluate the risk of epithelial ovarian cancer (EOC) recurrence in patients with rising serum cancer antigen 125 (CA-125) levels that remain below the upper limit of normal (< 35 U/mL). Patients and Methods All patients treated for EOC between September 1997 and March 2003 were identified and screened retrospectively for the following: (1) elevated serum CA-125 at time of diagnosis.
  5. Data clearly indicate that patients with recurrent mucinous ovarian cancer with a recurrence free interval higher than 6 months can respond to a platinum re-treatment, although the response rate is lower than that observed in non-mucinous cancer. Overall, recurrent mucinous cancer patients receive less chemotherapy lines than the others.
  6. Abstract: The treatment of newly diagnosed or recurrent ovarian cancer has changed significantly in recent years, with an increased number of treatment options available.Surgery and combination treatment with carboplatin and paclitaxel are the standard of care for patients with newly diagnosed disease, although the use of neoadjuvant chemotherapy is increasing
  7. Purpose: Mucinous ovarian carcinomas have a distinct clinical pattern compared with other subtypes of ovarian carcinoma. Here, we evaluated (i) stage-specific clinical significance of mucinous ovarian carcinomas in a large cohort and (ii) the functional role of Src kinase in preclinical models of mucinous ovarian carcinoma. Experimental Design: A total of 1,302 ovarian cancer patients.

MCs account for approximately 10-15% of benign ovarian neoplasms and 80% of all primary mucinous ovarian tumors 2, 3. MBOTs comprise 30-50% of borderline tumors and are more common than their invasive counterparts 4 Pignata S, Ferrandina G, Scarfone G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer 2008;8:252 Mucinous ovarian cancer (MOC) is a rare subtype of epithelial ovarian carcinoma (EOC). Whereas all EOC subtypes are addressed in the same way, MOC is a distinct entity. Appreciating the pathological features and genomic profile of MOC may result in the improvement in management and, hence, the prognosis. Distinguishing primary MOC from metastatic mucinous carcinoma can be challenging but is.

Previously Untreated Mucinous Ovarian Cancer . Stage II-IV or Recurrent Stage I Mucinous Carcinoma of Ovary (N = 332) Carboplatin AUC 5/6 Paclitaxel 175 mg/m 2 X 6 cycle The serum level of CA-125 is well established as a highly useful surrogate for monitoring the response to treatment and confirming relapse in women with epithelial ovarian cancer. 1-4 However, the literature has focused on the more common ovarian cancer histologies, particularly the serous subtype. 5-9 The prognostic value of CA-125 for clear cell or mucinous ovarian cancers is less certain

Delayed malignant melanoma recurrence simulating primaryPPT - Ovarian borderline tumors PowerPoint PresentationPoorly differentiated mucinous carcinoma with signet ringExtremely large epithelial ovarian cancer associated withPPT - Interactive Session Ovarian Cancer II PowerPoint

Ovarian cancer stage 1 indicates this type of cancer is in its early stages. Detecting ovarian cancer at stage 1 means treatment can start sooner, which improves a person's outlook. Learn more. A big concern for many patients with ovarian cancer is the high-rate of recurrence. Does that apply to these rare types? It is, unfortunately. All three of the rare epithelial types: clear cell, mucinous and low-grade serous are not very sensitive to the standard chemotherapy, which is typically Abraxane (paclitaxel) and Paraplatin (carboplatin) Study examines treatment options for women with recurrent ovarian cancer by Wiley Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour Recurrent Ovarian Cancer. About 80% of women with advanced-stage ovarian cancer more commonly have tumor progression or recurrence. Platinum free interval (PFI) is one of the most reliable predictors indicating the response of recurrent ovarian cancer to subsequent chemotherapy